| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England journal of medicine 364 (19), 1817-1825, 2011 | 7935 | 2011 |
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3051 | 2013 |
| Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial M Ychou, V Boige, JP Pignon, T Conroy, O Bouché, G Lebreton, ... Journal of clinical oncology 29 (13), 1715-1721, 2011 | 2346 | 2011 |
| Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 JP Gérard, T Conroy, F Bonnetain, O Bouché, O Chapet, ... Journal of clinical oncology 24 (28), 4620-4625, 2006 | 2174 | 2006 |
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ... Journal of clinical oncology 26 (3), 374-379, 2008 | 1956 | 2008 |
| Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 L Bedenne, P Michel, O Bouché, C Milan, C Mariette, T Conroy, D Pezet, ... Journal of clinical oncology 25 (10), 1160-1168, 2007 | 1423 | 2007 |
| Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ... The lancet oncology 14 (1), 29-37, 2013 | 1335 | 2013 |
| Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced … A de Gramont, JF Bosset, C Milan, P Rougier, O Bouché, PL Etienne, ... Journal of Clinical Oncology 15 (2), 808-815, 1997 | 1191 | 1997 |
| Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib … P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ... Jama 315 (17), 1844-1853, 2016 | 1021 | 2016 |
| Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2 JP Gérard, D Azria, S Gourgou-Bourgade, I Martel-Laffay, C Hennequin, ... Journal of clinical oncology 28 (10), 1638-1644, 2010 | 946 | 2010 |
| Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, ... Journal of clinical oncology 27 (35), 5924-5930, 2009 | 856 | 2009 |
| Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone … B Chauffert, F Mornex, F Bonnetain, P Rougier, C Mariette, O Bouché, ... Annals of oncology 19 (9), 1592-1599, 2008 | 802 | 2008 |
| Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial G Portier, D Elias, O Bouche, P Rougier, JF Bosset, J Saric, J Belghiti, ... Journal of Clinical Oncology 24 (31), 4976-4982, 2006 | 672 | 2006 |
| Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. E Mitry, AL Fields, H Bleiberg, R Labianca, G Portier, D Tu, D Nitti, V Torri, ... | 661 | 2008 |
| Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised … T Conroy, JF Bosset, PL Etienne, E Rio, É François, N Mesgouez-Nebout, ... The Lancet Oncology 22 (5), 702-715, 2021 | 616 | 2021 |
| Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients V Taly, D Pekin, L Benhaim, SK Kotsopoulos, D Le Corre, X Li, I Atochin, ... Clinical chemistry 59 (12), 1722-1731, 2013 | 536 | 2013 |
| Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial S Gourgou-Bourgade, C Bascoul-Mollevi, F Desseigne, M Ychou, ... J Clin Oncol 31 (1), 23-29, 2013 | 529 | 2013 |
| Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer JP Gérard, D Azria, S Gourgou-Bourgade, I Martel-Lafay, C Hennequin, ... Journal of clinical oncology 30 (36), 4558-4565, 2012 | 481 | 2012 |
| Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC … V Boige, J Pignon, B Saint-Aubert, P Lasser, T Conroy, O Bouché, ... Journal of Clinical oncology 25 (18_suppl), 4510-4510, 2007 | 435 | 2007 |
| Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial T Conroy, MP Galais, JL Raoul, O Bouché, S Gourgou-Bourgade, ... The lancet oncology 15 (3), 305-314, 2014 | 415 | 2014 |
